NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel - Wikidata - wikimedia - TriplyDB

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel

http://www.wikidata.org/entity/Q36612282

about

Tubulin-interactive natural products as anticancer agents Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel Clinical Translation of Nanomedicine.A Novel Gd-DTPA-conjugated Poly(L-γ-glutamyl-glutamine)-paclitaxel Polymeric Delivery System for Tumor Theranostics.Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities.A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.Efficient antitumor effect of co-drug-loaded nanoparticles with gelatin hydrogel by local implantation Advances of cancer therapy by nanotechnology.A simple method to improve the stability of docetaxel micelles Stimulus-responsive targeted nanomicelles for effective cancer therapy.Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction.Polymeric micelles as a new drug carrier system and their required considerations for clinical trials.Nanoparticles containing insoluble drug for cancer therapy.Paclitaxel drug delivery systems.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.Polymeric nanoparticles: the future of nanomedicine.Structural modifications in polymeric micelles to impart multifunctionality for improved drug delivery.Polypeptide/doxorubicin hydrochloride polymersomes prepared through organic solvent-free technique as a smart drug delivery platform.Doxorubicin conjugate of poly(ethylene glycol)-block-polyphosphoester for cancer therapy.Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate.Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.Diblock copolymers of polyethylene glycol and a polymethacrylamide with side-chains containing twin ortho ester rings: synthesis, characterization, and evaluation as potential pH-responsive micelles.Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T1-T2 Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics.A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy.Preliminary study on fabrication, characterization and synergistic anti-lung cancer effects of self-assembled micelles of covalently conjugated celastrol-polyethylene glycol-ginsenoside Rh2.

P2860

Q24650163-E90E6809-5EA2-4870-9FBC-E7E5DCDDAB79 Q26775004-88847C5A-B449-4ECE-9EA4-2ABBEC405009 Q28396304-0C2F690B-6A24-47D3-8085-8EEB68A51CF9 Q28481293-EDC6E980-F168-4B44-8EF9-D3B0CE584CD7 Q30355939-6F795345-B4E7-4FE1-AE16-73A490D5FE68 Q33812462-B316E85A-7969-4D17-B94F-05F1A250BD2B Q34119493-C37C69AA-E4AA-4232-9C65-E6C33DB86550 Q36610814-90C6FEAC-FEBB-418B-8C6C-9C4C1F1DA77F Q36937387-DF360690-292E-476F-916C-5BD8C3296E6D Q37234202-E7AAB92F-D6DA-4788-935F-C7DDC372FD11 Q37408420-4C684DF5-3516-473B-BADF-A55BC9A8B8BA Q37575475-3B3C6AB3-3D45-425E-A6DE-C7EA960AE6F5 Q37657516-06061576-5DA4-45BC-8A1E-9090704439F7 Q37679942-40C28036-3A2B-47DE-A1CE-00B49B163E0C Q37693046-B1540C1B-66F3-44C1-8632-101D924713F6 Q38071668-B9CB9BBE-FFF9-41FD-9355-67354A956413 Q38183786-26F70B4F-557F-4770-B113-77248688A131 Q38575282-FD4F1078-AE3C-434D-A911-14141F7F5CED Q38697200-08710DDC-D8C7-4B0F-9485-B41238A6C281 Q39119043-619480AD-7907-4DCE-920F-577DC93EBA27 Q39125938-E55180BF-693E-4B19-8651-4954B70DDAAE Q39377073-79A44BE2-D49E-47FE-B3BC-B3D5B3E09BBD Q39637131-0FAB950C-8AEB-4D20-9AE7-B0C30B936FA2 Q41953738-5BCEA7D7-CA9B-4FE3-8180-C2EAC73FD7F9 Q42833945-D773D7FB-536D-4140-8C11-44859FA660F5 Q47168995-A0CF5208-9E2B-4FF5-A953-1BF9D0B50A65 Q50681917-FD438BE6-9ED8-43A4-9273-4FA640FACCD3 Q53276308-7CFB5108-278D-4BAB-9C1F-AB412B41D7DF

P2860

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel

http://www.wikidata.org/entity/Q36612282

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@ast

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@en

type

label

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@ast

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@en

prefLabel

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@ast

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@en

P1433

Q36612282-457899F5-755F-43AB-8683-12B5ABC25D06

P1476

Q36612282-E0332331-4C37-4BFB-B292-977F417AB4E4

P2093

Q36612282-15B93E93-90FC-4710-A6BD-5AA2CD806370

Q36612282-2F8A4D57-6535-45DF-96FA-F26E6C252381

Q36612282-361557E3-D1B2-4B3F-B6EE-D67AA890DE1F

Q36612282-82AD683C-AF76-43F9-861E-B0D826631A73

Q36612282-C20D16D6-E0DF-402E-A2D5-814CF4849611

Q36612282-CFDB623F-A495-4D31-92B3-DE2AB62F776D

Q36612282-E7034DF9-4475-4573-98CA-5C5E958E7CB4

P2860

Q36612282-04D14347-AA9D-4F62-8258-E8595AD50E6A

Q36612282-07390EE3-F26B-424C-BA05-25148820C991

Q36612282-0795980E-A722-448E-B660-A6438AFBA759

Q36612282-225C6317-1C76-42BC-8BFB-9CF9955B1692

Q36612282-27BB9655-0AB2-47FA-BE0E-52C64C8403FB

Q36612282-28538BD6-23DF-4715-A303-CAEC2AB9C3DA

Q36612282-29201AA7-0AE2-4EAC-8D40-BE6E518BBD15

Q36612282-314DFE9E-BE38-429D-9B53-7FD1EF4F8951

Q36612282-3F0AE740-756F-4EB8-970E-8D3D441DD0EA

Q36612282-51F8DFE1-D79F-404E-9CEA-A257532996BE

P2888

Q36612282-2AACFD70-9D50-4AEA-BAAB-DA4EB6B789F2

P304

Q36612282-B059EF4D-9B94-4CEC-823E-3091AEFCAC72

P31

Q36612282-589B1845-C026-4F56-B817-F6A2F459E227

P356

Q36612282-D8741157-20FE-4E3B-B734-01C4A23A2EE3

P407

Q36612282-2BEF2A31-9BFC-4318-8855-80A3D12C7BD8

P433

Q36612282-789EBDF4-F611-4264-B819-B368F2DEA559

P478

Q36612282-4B40FBB8-0233-46A3-842E-623262646C8C

P577

Q36612282-A719C380-F5A8-4C66-8C52-BFBC4F280336

P5875

Q36612282-3594BB05-EEBE-4591-8C8D-4EC1FAD24073

P698

Q36612282-47606908-B898-47F9-A643-EBC02667FCD3

P921

Q36612282-0C1B48A4-C3CA-4C64-B825-0E2E81A7685A

P932

Q36612282-F02313E2-C71F-46AE-BF0D-6EA4C3A4E309

P356

P1433

British Journal of Cancer

P1476

NK105, a paclitaxel-incorporat ...... nt compared to free paclitaxel

@en

P2093

Kawaguchi T

http://www.w3.org/2001/XMLSchema#string

Koizumi F

http://www.w3.org/2001/XMLSchema#string

Kuroda J

http://www.w3.org/2001/XMLSchema#string

Matsumura Y

http://www.w3.org/2001/XMLSchema#string

Naito S

http://www.w3.org/2001/XMLSchema#string

Negishi T

http://www.w3.org/2001/XMLSchema#string

Uchino H

http://www.w3.org/2001/XMLSchema#string

P2860

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

Taxol in the management of cancers of the breast and the ovary.

Paclitaxel (taxol)

Radiation and third-generation chemotherapy.

Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.

Simple method of estimating severity of pulmonary fibrosis on a numerical scale

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

Tumoritropic and lymphotropic principles of macromolecular drugs.

Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.

P2888

P304

601-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603311

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6878674

http://www.w3.org/2001/XMLSchema#string

P698

16909136

http://www.w3.org/2001/XMLSchema#string

P921

P932

2360685

http://www.w3.org/2001/XMLSchema#string